Whalesbook
Sai Life Sciences has announced strong financial results for fiscal year 2026, with revenue increasing 29% to ₹2,192 Crore and net profit surging 109% to ₹355 Crore. The company also unveiled plans for a significant ₹1100-1300 Crore capital expenditure for FY27, signaling aggressive expansion in its Contract Research, Development, and Manufacturing Organization (CRDMO) services in response to rising customer demand.
In FY26, revenue grew 29% year-over-year to ₹2,192 Crore from ₹1,695 Crore in FY25. Profit After Tax (PAT) more than doubled, climbing 109% to ₹355 Crore from ₹170 Crore. Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) also saw robust growth, rising 56% to ₹661 Crore. This performance improved the EBITDA margin to 30% from 25% in the previous year.
The planned ₹1100-1300 Crore capital expenditure for FY27 is earmarked for expanding its CRDMO services. This investment underscores the company's strategic intent to scale operations and enhance its competitive edge in the global pharmaceutical outsourcing market. Sai Life Sciences operates as a global CRDMO, providing integrated services from discovery to commercial manufacturing for pharmaceutical and biotech firms worldwide, focusing on end-to-end solutions.
Looking forward, the company aims to sustain a medium-term revenue compound annual growth rate (CAGR) of 15-20%. Profitability is expected to remain strong, with a target to maintain EBITDA margins between 28% and 30%. This expansion drive is crucial for capturing emerging opportunities in outsourced drug development and manufacturing.
However, the company faces potential risks. Geopolitical uncertainties could impact input and logistics costs, while navigating the evolving global tariff environment will be key to mitigating cost pressures.
In the competitive life sciences CRDMO sector, Sai Life Sciences competes with players like Syngene International, which also emphasizes integrated services and capacity expansion. Laurus Labs, while primarily an API manufacturer, has expanded its CDMO offerings, positioning it as another competitor for outsourcing contracts.